Drug target · SLC18A2
VMAT2
Vesicular monoamine transporter 2
1 compound in the CNS pipeline acts on VMAT2.
Compounds targeting VMAT2
| Compound | Action | Affinity | Lead program | Developer |
|---|---|---|---|---|
| NBI-1065890primarySmall molecule | Inhibitor | — | Phase 2Tardive Dyskinesia | Neurocrine Biosciences, Inc. |